In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vical, Vascular Genetics, HGS end gene drug deal

Executive Summary

Human Genome Sciences (gene- and protein-based drugs), Vascular Genetics (gene therapy products for vascular disease), and Vical (gene-based vaccines), will develop genes as pharmaceuticals to prevent and treat various diseases. The collaboration will use Vical's naked DNA delivery technology, genes in HGS' database, and products in development at Vascular Genetics.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract
    • Product or Technology Swap
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register